Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
Provided By GlobeNewswire
Last update: Nov 21, 2024
- Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data -
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, is proud to announce two upcoming presentations at the American Epilepsy Society 2024 Annual Meeting in Los Angeles, December 6-10, 2024.
Read more at globenewswire.com
